WO2018133106A1 - Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications - Google Patents
Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications Download PDFInfo
- Publication number
- WO2018133106A1 WO2018133106A1 PCT/CN2017/072226 CN2017072226W WO2018133106A1 WO 2018133106 A1 WO2018133106 A1 WO 2018133106A1 CN 2017072226 W CN2017072226 W CN 2017072226W WO 2018133106 A1 WO2018133106 A1 WO 2018133106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- saponin
- solid dispersion
- povidone
- solution
- preparation
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000007949 saponins Chemical class 0.000 claims description 64
- 229930182490 saponin Natural products 0.000 claims description 57
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 55
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 22
- 229940069328 povidone Drugs 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 210000001185 bone marrow Anatomy 0.000 claims description 14
- 229920003081 Povidone K 30 Polymers 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 210000003743 erythrocyte Anatomy 0.000 claims description 12
- 210000005259 peripheral blood Anatomy 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 206010065553 Bone marrow failure Diseases 0.000 claims description 10
- 102000001554 Hemoglobins Human genes 0.000 claims description 10
- 108010054147 Hemoglobins Proteins 0.000 claims description 10
- 210000001772 blood platelet Anatomy 0.000 claims description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 210000000440 neutrophil Anatomy 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 49
- 239000000243 solution Substances 0.000 description 40
- 238000004090 dissolution Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000012876 carrier material Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 244000173853 Sanguisorba officinalis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- -1 Diquat Saponin Chemical class 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the invention relates to a saponin solid dispersion, a preparation method thereof and a use thereof, and belongs to the field of medicine.
- Myelosuppression is a clinically common hematopoietic disease that can occur in radiation therapy and/or chemotherapy of various systemic neoplastic diseases, radiation damage caused by ionizing radiation, viral hepatitis, parvovirus infection or drugs (chloramphenicol). , benzene, sulfonamides, anti-epileptic drugs, sedatives, anti-thyroid drugs, anti-diabetes drugs, anti-malaria, sleeping pills and other factors. Myelosuppression can cause damage to the bone marrow microenvironment, hematopoietic stem cells, hematopoietic growth factors, etc., and the granulosa, red, and megakaryocyte systems are inhibited.
- the saponin is extracted from the roots of Sanguisorba officinalis L. or S. officinalis L. var. longifolia (Bertol.) Yu et Li.
- the active ingredient is an aglycon of saponin I and saponin II, chemical name: 3 ⁇ , 19 ⁇ -hydroxy-Uso-12--28-carboxylic acid, and its structural formula is as follows:
- CN101119740A discloses the use of saponin II in the preparation of a medicament for increasing red blood cells and hemoglobin. In actual use, it was found that the saponin has poor efficacy, and when used alone, the effect of increasing blood cell level and treating bone marrow suppression is poor, which greatly limits the clinical application of saponin.
- the object of the present invention is to provide a saponin solid dispersion, a preparation method thereof and use thereof.
- the present invention provides a solid dispersion of saponin, which is prepared from a raw material of the following weight ratio: 1 part of saponin and 2 to 30 parts of povidone.
- povidone is PVP K30.
- the invention also provides a preparation method of the above solid dispersion, comprising the following steps:
- the organic solvent described in the step a is anhydrous ethanol.
- the invention also provides the use of a solid dispersion as described above for the manufacture of a medicament for the treatment and/or prevention of myelosuppression.
- the drug is a drug for treating and/or preventing bone marrow suppression caused by a chemical substance.
- the present invention also provides the use of the above solid dispersion for the preparation of a medicament for increasing the number of one or more of peripheral blood leukocytes, neutrophils, red blood cells, platelets, hemoglobin, bone marrow hematopoietic stem cells.
- the invention also provides a method of treating and/or preventing myelosuppression, in particular using the solid dispersion described above.
- the method is a method of treating and/or preventing bone marrow suppression caused by a chemical substance.
- the present invention also provides a method for increasing the amount of one or more of peripheral blood leukocytes, neutrophils, red blood cells, platelets, hemoglobin, bone marrow hematopoietic stem cells, in particular, using the aforementioned solid dispersion.
- the present invention provides a saponin solid dispersion and a preparation method thereof.
- the solid dispersion of saponin prepared by the invention can significantly improve the solubility and dissolution of the drug, and significantly increase the number of peripheral blood leukocytes, neutrophils, red blood cells, platelets, hemoglobin and bone marrow hematopoietic stem cells, and the effect is significantly better than the ground.
- the original drug of saponin has obvious effects of treating and/or preventing myelosuppression.
- the raw materials and equipment used in the specific embodiments of the present invention are known products and are obtained by purchasing commercially available products.
- the solution 2 was stirred on a thermostatic magnetic stirrer while the solution 1 was slowly added to the solution 2 with a dropper. After the solution 1 was all added to the solution 2, the mixture was stirred on a thermostatic magnetic stirrer for four hours. The mixture was poured into an evaporating dish, placed in a 60 ° C water bath, evaporated to dryness, and the dried product was finely ground to obtain a solid dispersion.
- the solution 2 was stirred on a thermostatic magnetic stirrer while the solution 1 was slowly added to the solution 2 with a dropper. After the solution 1 was all added to the solution 2, the mixture was stirred on a thermostatic magnetic stirrer for four hours. The mixture was poured into an evaporating dish, placed in a 60 ° C water bath, evaporated to dryness, and the dried product was finely ground to obtain a solid dispersion.
- the solution 2 was stirred on a thermostatic magnetic stirrer while the solution 1 was slowly added to the solution 2 with a dropper. After the solution 1 was all added to the solution 2, the mixture was stirred on a thermostatic magnetic stirrer for four hours. The mixture was poured into an evaporating dish, placed in a 60 ° C water bath, evaporated to dryness, and the dried product was finely ground to obtain a solid dispersion.
- Dissolution method Take one tablet of each batch, according to the dissolution method ("Chinese Pharmacopoeia" Appendix XC second method), with pH 6.8PBS 1 000mL as the dissolution medium, the rotation speed is 100r ⁇ min -1 , temperature ( 37 ⁇ 0.5)°C, sample 5mL at 0, 5, 15, 20, 25min, filter with 0.45 ⁇ m microporous membrane, place the filtrate in a 100mL volumetric flask, dilute to the mark with pH 6.8PBS, shake well, and UV- Visible spectrophotometry (Chinese Pharmacopoeia Appendix IVA) measured absorbance at 345nm wavelength; after 25min sampling, the whole solution was transferred to a beaker, heated and stirred at 100 ° C for 2 ⁇ 3min, cooled to 37 ° C, according to the above method After sampling and dilution, the absorbance measured by the eluate after treatment at 100 ° C was the denominator, and the absorbance measured at each time point was taken as
- the solubility of the original drug of the saponin was measured in the early stage of the experiment, which was only 0.021 mg/ml. It can be seen from Table 1 that when the solid dispersion of saponin is prepared by using the povidone of the present invention, the solubility and dissolution of the drug are the highest, which is significantly better than other carrier materials (P ⁇ 0.05); if other carrier materials, such as Pollock, are used, With sam, polyethylene glycol, etc., the dissolution rate of the solid dispersion is greatly reduced, and the solubility of the drug is not as obvious as that of PVP K30.
- test drug saponin solid dispersion group prepared according to Example 2
- saponin group saponin group
- tool drugs cyclophosphamide.
- mice All animals were fed ad libitum for 1 week and were randomly divided into: blank group; model group; saponin solid dispersion group, powder must be formulated into 0.5mg ⁇ kg -1 , 5mg ⁇ kg -1 , 10mg ⁇ kg -1 suspension, prepared before use; saponin group, formulated into 10mg ⁇ kg -1 suspension, prepared before use.
- the other groups of mice were intraperitoneally injected with cyclophosphamide physiological saline solution at a dose of 50 mg ⁇ kg -1 for 3 consecutive days, and the blank mice were injected with the same volume of normal saline in the tail vein.
- mice in the blank group and the model group were intragastrically administered with the same volume of normal saline for 7 consecutive days.
- Peripheral blood test Peripheral blood leukocytes (WBC), neutrophils (NEUT), red blood cells (RBC), platelets (PLT), and hemoglobin (HGB) were counted in each experimental group using an automatic blood cell counter. .
- Bone marrow hematopoietic stem cell count (based on bone marrow cell CD34 + antigen expression), the right femur bone marrow cells were washed out with PBS buffer containing bovine serum albumin at a concentration of 0.2%, and 10 6 cells were removed and centrifuged. The supernatant was added with 30 ⁇ L of normal mouse serum to block the non-specific binding site, and then 10 ⁇ L of FITC-labeled rat anti-mouse CD34 + antibody was added, 10 ⁇ L of the corresponding control antibody was added to the control tube, and the reaction was incubated at 4 ° C for 30 min in the dark.
- the number of hematopoietic stem cells in the saponin solid dispersion group of the present invention was significantly increased (P ⁇ 0.05), and there was no significant difference in the saponin group;
- the number of hematopoietic stem cells in the saponin solid dispersion group of the present invention was significantly increased (P ⁇ 0.05).
- the solid dispersion of saponin prepared by the invention effectively solves the problem of low solubility of the saponin, improves the bioavailability of the saponin, thereby improving the therapeutic effect of raising blood cells, and effectively preventing and treating bone marrow suppression. It is of great significance for the clinical application of saponin.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne une dispersion solide de ziyuglucoside II de Sanguisorba officinalis, son procédé de préparation et ses applications, la formulation de la disperson solide de ziyuglucoside II de Sanguisorba officinalis étant constituée des excipients suivants, exprimés en poids : 1 partie de ziyuglucoside de Sanguisorba officinalis et 2-30 parties de polyvinylpyrrolidone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/072226 WO2018133106A1 (fr) | 2017-01-23 | 2017-01-23 | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/072226 WO2018133106A1 (fr) | 2017-01-23 | 2017-01-23 | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018133106A1 true WO2018133106A1 (fr) | 2018-07-26 |
Family
ID=62907576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/072226 WO2018133106A1 (fr) | 2017-01-23 | 2017-01-23 | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018133106A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593436A (zh) * | 2003-09-08 | 2005-03-16 | 成都地奥制药集团有限公司 | 乌索烷型三萜皂苷在制备升高白细胞和/或血小板药物中的应用 |
CN1788758A (zh) * | 2004-12-14 | 2006-06-21 | 成都地奥制药集团有限公司 | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 |
CN103690549A (zh) * | 2012-12-24 | 2014-04-02 | 江西本草天工科技有限责任公司 | ɑ-常春藤皂苷固体分散体及其环糊精包合物的制备 |
CN106580884A (zh) * | 2015-10-16 | 2017-04-26 | 四川英路维特医药科技有限公司 | 一种地榆皂苷元固体分散体及其制备方法、用途 |
-
2017
- 2017-01-23 WO PCT/CN2017/072226 patent/WO2018133106A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593436A (zh) * | 2003-09-08 | 2005-03-16 | 成都地奥制药集团有限公司 | 乌索烷型三萜皂苷在制备升高白细胞和/或血小板药物中的应用 |
CN1788758A (zh) * | 2004-12-14 | 2006-06-21 | 成都地奥制药集团有限公司 | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 |
CN103690549A (zh) * | 2012-12-24 | 2014-04-02 | 江西本草天工科技有限责任公司 | ɑ-常春藤皂苷固体分散体及其环糊精包合物的制备 |
CN106580884A (zh) * | 2015-10-16 | 2017-04-26 | 四川英路维特医药科技有限公司 | 一种地榆皂苷元固体分散体及其制备方法、用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103893246A (zh) | 广金钱草总黄酮胶囊及其制备方法和应用 | |
CN101301455A (zh) | 一种治疗高脂血症的中药复方姜黄固体分散体 | |
CN107595782A (zh) | 一种利奈唑胺干混悬剂及其制备方法 | |
CN110559272B (zh) | 一种抗乳腺癌纳米药物及其制备方法 | |
WO2018133106A1 (fr) | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications | |
CN102018736A (zh) | 一种青黛饮片及其制备方法 | |
CN106581692A (zh) | 一种地榆皂苷i包合物及其制备方法 | |
WO2018133105A1 (fr) | COMPLEXE D'INCLUSION D'HYDROXYPROPYL-β-CYCLODEXTRINE DE ZIYUGLUCOSIDE II DE SANGUISORBA OFFICINALIS, SON PROCÉDÉ DE PRÉPARATION ET SES APPLICATIONS | |
WO2018133110A1 (fr) | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation | |
WO2018133112A1 (fr) | Injection d'aglycone de sanguisorba officinalis, son procédé de préparation et ses applications | |
CN108853017B (zh) | 一种雌三醇纳米口服制剂的组方与制备工艺 | |
WO2017181653A1 (fr) | Micelle polymère à base de sapogénine de radix sanguisorbae, son procédé de préparation, et son utilisation pharmaceutique | |
WO2018133104A1 (fr) | COMPLEXE D'INCLUSION D'HYDROXYPROPYL-β-CYCLODEXTRINE DE ZIYUGLUCOSIDE II DE SANGUISORBA OFFICINALIS, SON PROCÉDÉ DE PRÉPARATION ET SES APPLICATIONS | |
US10493029B2 (en) | Ziyuglycoside II polymer micelle and preparative methods thereof | |
WO2018133109A1 (fr) | Liposome de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation | |
CN103159710B (zh) | 用于抗病毒的十氢萘衍生物 | |
CN106580881A (zh) | 一种地榆苷元脂质体及其制备方法、用途 | |
CN106214646A (zh) | 一种水飞蓟宾葡甲胺制剂 | |
WO2018133108A1 (fr) | Émulsion de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation | |
WO2018133113A1 (fr) | Liposome d'aglycone de sanguisorba officinalis, son procédé de préparation et ses applications | |
CN111658708A (zh) | 一种改善贫血症状的组合物及其制备方法和应用 | |
CN106539763A (zh) | 一种地榆皂苷ⅱ固体分散体及其制备方法 | |
CN112438971A (zh) | 蛋氨酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 | |
CN106580884A (zh) | 一种地榆皂苷元固体分散体及其制备方法、用途 | |
CN110856746A (zh) | 一种含卡非佐米的胶束冻干制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17892187 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17892187 Country of ref document: EP Kind code of ref document: A1 |